SEC Form S-8 filed by Tevogen Bio Holdings Inc.
As filed with the Securities and Exchange Commission on May 1, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Tevogen Bio Holdings Inc.
(Exact name of registrant as specified in its charter)
Delaware | 98-1597194 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
15 Independence Boulevard, Suite #410 Warren, New Jersey 07059 |
07059 | |
(Address of Principal Executive Offices) | (Zip Code) |
Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan
(Full title of the plan)
Ryan Saadi
Chief Executive Officer
Tevogen Bio Holdings Inc.
15 Independence Boulevard, Suite #410
Warren, New Jersey 07059
(Name and address of agent for service)
(877) 838-6436
(Telephone number, including area code, of agent for service)
Copies to:
William I. Intner
J. Nicholas Hoover
Hogan Lovells US LLP
100 International Drive, Suite 2000
Baltimore, Maryland 21202
(410) 659-2700
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
Tevogen Bio Holdings Inc. (the “Company”) is filing this registration statement with the Securities and Exchange Commission (the “SEC”) to register the sale and issuance of up to 8,899,568 additional shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), authorized for issuance pursuant to awards under the Company’s 2024 Omnibus Incentive Plan (the “Plan”), pursuant to the provisions of the Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the Plan on January 1, 2025. The Company previously registered the sale of shares of Common Stock under the Plan on a registration statement on Form S-8 filed with the SEC on June 10, 2024 (File No. 333-280075) (the “Prior Registration Statement”).
Pursuant to General Instruction E to Form S-8, this registration statement hereby incorporates by reference the contents of the Prior Registration Statement except as set forth below.
i |
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
* | Filed herewith. |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Warren, State of New Jersey, on this 1st day of May, 2025.
TEVOGEN BIO HOLDINGS INC. | ||
By: | /s/ Ryan Saadi |
|
Ryan Saadi | ||
Chief Executive Officer and Chairperson of the Board of Directors |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ryan Saadi and Kirti Desai, and each of them, such person’s true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement, and any registration statement relating to the offering covered by this registration statement and filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or such person’s substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Ryan Saadi |
Chief Executive Officer and Chairperson of the Board of Directors | May 1, 2025 | ||
Ryan Saadi | (Principal Executive Officer) | |||
/s/ Kirti Desai |
Chief Financial Officer | May 1, 2025 | ||
Kirti Desai | (Principal Financial Officer and Principal Accounting Officer) | |||
/s/ Jeffrey Feike |
Director | May 1, 2025 | ||
Jeffrey Feike | ||||
/s/ Dr. Keow Lin Goh |
Director | May 1, 2025 | ||
Dr. Keow Lin Goh | ||||
/s/ Dr. Curtis Patton |
Director | May 1, 2025 | ||
Dr. Curtis Patton | ||||
/s/ Susan Podlogar |
Director | May 1, 2025 | ||
Susan Podlogar | ||||
/s/ Victor Sordillo |
Director | May 1, 2025 | ||
Victor Sordillo |
3 |